Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and varlilumab in relapsed or refractory B-cell lymphoma
ISRCTN15025004Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of rituximab and varlilumab in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 3 more (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoints: Safety and Efficacy. Started Sep 2017; status: completed.
02
Drugs
rituximabvarlilumab
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ISRCTN15025004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15025004.